Insmed (NASDAQ:INSM) Announces Earnings Results

09 May 2026, 23:38 by Doug Wharley · The Cerbat Gem

Insmed (NASDAQ:INSM – Get Free Report) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.14, FiscalAI reports. Insmed had a negative return on equity of 121.03% and a negative net margin of 144.44%.The firm had revenue of $305.96 million during the quarter, compared to the consensus estimate of $300.81 million. During the same period last year, the business posted ($1.42) EPS. The business’s revenue was up 229.7% compared to the same quarter last year.

Here are the key takeaways from Insmed’s conference call:

BRINSUPRI launch is exceeding expectations with 44% sequential growth in Q1, >80% patient enrollment in the inLighten support program, ~90% specialty pharmacy approval rates, and management reiterates at least $1 billion in 2026 revenue guidance.
Phase IIIb ENCORE for ARIKAYCE showed statistically significant improvement in patient‑reported respiratory symptoms and durable culture conversion, prompting plans to submit to US and Japanese regulators for a label expansion that could grow the addressable market from ~30k to >200k patients.
TPIP is advancing through late‑stage development with the PALM‑PAH Phase III program open and PALM‑ILD enrolling across multiple countries, and OLE data (expected Q3) show some patients titrated to higher doses (up to 1,280 mcg), supporting dose feasibility for Phase III.
Financially the company reported approximately $1.2 billion in cash and marketable securities and expects to achieve sustainable cash‑flow positivity in 2027 without raising additional capital, while Q1 gross‑to‑net metrics were within guided ranges.
International rollout faces uncertainty from MFN/pricing dynamics—Insmed has paused broader Europe/U.K. commercialization due to potential price controls, which poses a material risk to international revenue expansion.

Insmed Stock Down 3.6%

NASDAQ:INSM traded down $3.83 on Friday, hitting $101.17. The stock had a trading volume of 8,587,159 shares, compared to its average volume of 2,289,634. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. Insmed has a 52 week low of $64.85 and a 52 week high of $212.75. The business’s fifty day moving average is $145.87 and its 200 day moving average is $165.46. The company has a market cap of $21.84 billion, a PE ratio of -17.60 and a beta of 0.89.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Raymond James Financial assumed coverage on Insmed in a research report on Friday, April 10th. They set an “outperform” rating and a $200.00 target price on the stock. Barclays boosted their price target on Insmed from $231.00 to $237.00 and gave the company an “overweight” rating in a research note on Wednesday, April 1st. Royal Bank Of Canada cut their price target on Insmed from $220.00 to $205.00 and set an “outperform” rating on the stock in a report on Friday. Roth Mkm reaffirmed a “buy” rating and set a $212.00 price objective on shares of Insmed in a research report on Friday, April 17th. Finally, Jefferies Financial Group started coverage on shares of Insmed in a research report on Monday, March 16th. They set a “buy” rating and a $228.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $211.86.

Get Our Latest Stock Report on Insmed

Key Headlines Impacting Insmed

Here are the key news stories impacting Insmed this week:

Positive Sentiment: Insmed reported Q1 EPS of -$0.76, beating estimates, and revenue rose 229.7% year over year to $306 million. The company also reiterated major 2026 commercial goals, including at least $1 billion in BRINSUPRI revenue and $450 million to $470 million in ARIKAYCE revenue. Article: Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
Positive Sentiment: Analysts at Royal Bank of Canada and Wells Fargo cut their price targets but kept bullish ratings, signaling they still see meaningful upside from current levels. RBC lowered its target to $205 from $220 and Wells Fargo cut to $160 from $177. Article: Benzinga report on RBC price target cut Article: The Fly report on Wells Fargo price target cut
Neutral Sentiment: Insmed also highlighted progress on its pipeline and commercialization efforts, including positive ENCORE study results for ARIKAYCE and the start of the PALM-PAH study for TPIP. These updates support the long-term story, but they are less likely to move the stock immediately. Article: Insmed Q1 2026 Financial Results and Business Update
Negative Sentiment: The stock is under pressure because Q1 sales came in below expectations and the company’s implied 2026 revenue guidance was below consensus, raising concerns that launch momentum may not be matching investor hopes. Article: Insmed’s Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
Negative Sentiment: Higher first-quarter expenses also weighed on sentiment, with market commentary pointing to increased costs as another reason investors sold the shares after earnings. Article: Insmed Shares Tumble Amid Higher 1Q Expenses

Insider Activity

In related news, CEO William Lewis sold 10,699 shares of the stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $143.97, for a total value of $1,540,335.03. Following the transaction, the chief executive officer directly owned 301,185 shares in the company, valued at $43,361,604.45. This trade represents a 3.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Michael Alexander Smith sold 19,638 shares of Insmed stock in a transaction on Monday, March 30th. The shares were sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the sale, the insider directly owned 51,871 shares of the company’s stock, valued at approximately $7,831,483.58. The trade was a 27.46% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 174,589 shares of company stock worth $27,441,807 over the last quarter. 2.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. EverSource Wealth Advisors LLC raised its position in Insmed by 65.6% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 664 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 263 shares during the last quarter. First Trust Advisors LP boosted its holdings in Insmed by 80.8% during the 2nd quarter. First Trust Advisors LP now owns 47,392 shares of the biopharmaceutical company’s stock worth $4,770,000 after acquiring an additional 21,176 shares during the last quarter. Baird Financial Group Inc. bought a new stake in shares of Insmed in the 2nd quarter worth $2,589,000. Amundi raised its holdings in shares of Insmed by 21,194.4% in the second quarter. Amundi now owns 11,499 shares of the biopharmaceutical company’s stock valued at $1,130,000 after purchasing an additional 11,445 shares during the last quarter. Finally, Natixis purchased a new stake in shares of Insmed in the second quarter valued at about $1,072,000.

Insmed Company Profile

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.